1. Value in Health Regional Issues
Cost-Effectiveness Analysis of Ticagrelor and Prasugrel for the Treatment of Acute Coronary Syndrome 
Ying Jiao Zhao, PhD, Ai Leng Khoo, PhD, Liang Lin, MSc (iHTA), Monica Teng, MHSc, Tuck Seng Wu, MHSM, Mark Y. Chan, MBBS, MHS, Boon Peng Lim, BPharm 
Value in Health Regional Issues 
Volume 9, Pages (May 2016)
DOI: /j.vhri
Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Schematic Representation of Model Structure. Markov model yearly transitions through the following states: no-event state, non-fatal MI, non-CABG-related major bleeding, dyspnoea and death due to any causes.
Value in Health Regional Issues 2016 9, 22-27DOI: ( /j.vhri )
Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Tornado Diagram of One-way Sensitivity Analysis. Each horizontal bar in the tornado diagram represents ICER per QALY expected from a range of values evaluated for each variable. The upper and lower limits of each value used are listed next to each bar. The vertical line represents ICER per QALY determined from the base-case analysis.
Value in Health Regional Issues 2016 9, 22-27DOI: ( /j.vhri )
Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Cost-effectiveness Acceptability Curve. The probability of ticagrelor and prasugrel being cost-effective as compared to generic clopidogrel was 77.1% and 64.6% respectively, based on a threshold value of SGD 30,000. At a threshold value of SGD 60,000, the probability for prasugrel and ticagrelor became 86.9% and 88.3% respectively.
Value in Health Regional Issues 2016 9, 22-27DOI: ( /j.vhri )
Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions